ZPD‐L1 modification not only endowed AMZ with stronger tumor targeting, but also effectively blocked PD‐1/PD‐L1 interaction, terminating T cell immunosuppression and achieving ICD‐PD‐1/PD‐L1 synergistic immunotherapy. This evidence concerns the gene CD274 and neoplasm.